Abiomed (ABMD) Receives Health Canada Approval for Impella cVAD

6/14/2012 10:06:24 AM

DANVERS, Mass., June 14, 2012 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of break-through heart support technologies, today announced it has received Health Canada approval to market the Impella cVAD device, a new percutaneous Impella® heart pump that provides peak flow of approximately 4 liters of blood per minute.

Read at GlobeNewswire

Read Article at

Related Companies

News Categories

• GlobeNewswire

• Health Canada

• Abiomed

• Medical Dev. & Diag. - Approvals

• Medical Devices